alexa Expression signatures in lung cancer reveal a profile for EGFR-mutant tumours and identify selective PIK3CA overexpression by gene amplification.


Journal of Clinical & Experimental Pathology

Author(s): Angulo B, SuarezGauthier A, LopezRios F, Medina PP, Conde E,

Abstract Share this page

Abstract The development of targeted therapies creates a need to discriminate tumours accurately by their histological and genetic characteristics. Here, we aim to identify gene expression profiles and single markers that recapitulate the pathological and genetic background of non-small cell lung cancer (NSCLC). We performed cDNA microarray analysis on a series of 69 NSCLCs, with known mutation status for important genes, and six normal lung tissues. Unsupervised cluster analysis segregated normal lungs from lung tumours and lung tumours according to their histopathology and the presence of EGFR mutations. Several transcripts were highly overexpressed (by approximately 20 times) in squamous cell carcinomas (SCCs) relative to adenocarcinomas (ACs) and confirmed by immunohistochemistry in an independent cohort of 75 lung tumours. Expression of 13 genes constituted the most prominent hallmarks of EGFR-mutant tumours, including increased levels of proline dehydrogenase (PRODH) and down-regulation of X-box binding protein 1 (XBP1). No genes were differentially expressed, with a fold change >or= 4 or
  • DOI: 10.1002/path.2267
  • This article was published in J Pathol and referenced in Journal of Clinical & Experimental Pathology

    Relevant Expert PPTs

    Relevant Speaker PPTs

    • Ildiko Molnar
      The role of tissue-specific type 2 5’-deiodinase enzyme activities in Graves’ orbitopathy and systemic sclerosis: a new candidate in thyroid autoimmunity
      PDF Version
    • Abulkhair Beatti
      A new understanding of interferential current energy transfer in tissue
      PPT Version | PDF Version
    • Daisuke Ota
      The clinical outcome of reconstruction with tissue expander for breast cancer patients with mastectomy
      PPT Version | PDF Version
    • Wayne Grant Carter
      PPT Version | PDF Version
    • Vicente Marco
      Changes in breast cancer pathology reports after second opinion
      PPT Version | PDF Version
    • Jan Voskuil
      How antibodies can prevent medical progress and how they can be great tools?
      PPT Version | PDF Version
    • Mehmet Ozler
      “Mehmet Ozler-Gulhane-Military-Medical-Academy-Ankara-Turkey-Pinealectomy-Initiates-the-Oxidative-Stress-Response-in-Brain-Tissue-of-Rats-Subject-to-Abdominal-Surgery”
      PPT Version | PDF Version
    • Yosef Yarden
      Classically, the 3’untranslated region (3’UTR) is that region in eukaryotic protein-coding genes from the translation termination codon to the polyA signal. It is transcribed as an integral part of the mRNA encoded by the gene. However, there exists another kind of RNA, which consists of the 3’UTR alone, without all other elements in mRNA such as 5’UTR and coding region. The importance of independent 3’UTR RNA (referred as I3’UTR) was prompted by results of artificially introducing such RNA species into malignant mammalian cells. Since 1991, we found that the middle part of the 3’UTR of the human nuclear factor for interleukin-6 (NF-IL6) or C/EBP gene exerted tumor suppression effect in vivo. Our subsequent studies showed that transfection of C/EBP 3’UTR led to down-regulation of several genes favorable for malignancy and to up-regulation of some genes favorable for phenotypic reversion. Also, it was shown that the sequences near the termini of the C/EBP 3’UTR were important for its tumor suppression activity. Then, the C/EBP 3’UTR was found to directly inhibit the phosphorylation activity of protein kinase CPKC in SMMC-7721, a hepatocarcinoma cell line. Recently, an AU-rich region in the C/EBP 3’UTR was found also to be responsible for its tumor suppression. Recently we have also found evidence that the independent C/EBP 3’UTR RNA is actually exists in human tissues, such as fetal liver and heart, pregnant uterus, senescent fibroblasts etc. Through 1990’s to 2000’s, world scientists found several 3’UTR RNAs that functioned as artificial independent RNAs in cancer cells and resulted in tumor suppression. Interestingly, majority of genes for these RNAs have promoter-like structures in their 3’UTR regions, although the existence of their transcribed products as independent 3’UTR RNAs is still to be confirmed. Our studies indicate that the independent 3’UTR RNA is a novel non-coding RNA species whose function should be the regulation not of the expression of their original mRNA, but of some essential life activities of the cell as a whole.
      PPT Version | PDF Version
    • Kazuo Yano
      Regulatory approval for autologous human cells and tissue products in the United States, the European Union, and Japan
      PPT Version | PDF Version
    • William Lindsey
      Ultra-refined Follicular Unit Transplantation into scar tissue as an alternative to surgical scar revision in hair bearing scalp
      PPT Version | PDF Version
    • Simin Fazelipour
      “Simin Fazelipour-Islamic-Azad-University-Tehran-Medical-Sciences-Branch-Tehran-Iran-evaluation-of-histopathologic-and-histomorphometric-changes-of-adrenal-gland-tissue-following-consumption-of-Methylphenidate-in-male-mice”
      PPT Version | PDF Version
    • Momiao Xiong
      Integrative Image and RNA-seq Data Analysis
      PPT Version | PDF Version
    • Mehmet Saydam
      Quality-of- life, body image and cosmesis after single incision laparoscopic cholecystectomy versus laparoscopic cholecystectomy
      PPT Version | PDF Version
    • Jan O Gordeladze
      Key regulatory junctions stabilizing the osteoblast phenotype: Implications for cell and tissue engineering
      PPT Version | PDF Version
    • S K Dhattarwal
      PPT Version | PDF Version

    Recommended Conferences

    Peer Reviewed Journals
    Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
    International Conferences 2017-18
    Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

    Contact Us

    © 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version